MEDIPOST, Inc. Expands U.S. Presence with Key Executive Appointments, advances toward Phase III clinical trial of CARTISTEM® in North America
MEDIPOST, Inc. appoints 5 senior executives as part of the company’s journey to bring its flagship regenerative therapy, CARTISTEM®, to the U.S.
Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline
Merus N.V. (NASDAQ:MRUS) and Partner Therapeutics Inc, a private biotechnology company focused on hematology and oncology, ...
Merus, Partner Therapeutics enter agreement for Zenocutuzumab commercialization
N.V. and Partner Therapeutics, Inc., a private, fully-integrated biotechnology company with a focus in hematology and oncology, announced they have entered into an agreement in which Merus has ...
Targeted Oncology23h
November 2024 FDA Updates: Key Developments in Oncology
The FDA granted approval to nilotinib (Danziten) on November 14, 2024, for the treatment of adult patients with newly ...
Merus, Partner Therapeutics Ink Deal To Commercialize Zenocutuzumab In US, Stock Up In Pre-Market
Monday announced an agreement with Partner Therapeutics, Inc. to commercialize Zenocutuzumab for the treatment of ...